MYRIAD GENETICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $824.5M | $837.6M | $753.2M | $678.4M | $690.6M | $557.1M | $851.1M |
| Cost of Revenue | — | $247.9M | $252.2M | $236.2M | $202.0M | — | — | — |
| Gross Profit | — | $576.6M | $585.4M | $517.0M | $476.4M | — | — | — |
| Gross Margin | — | 69.9% | 69.9% | 68.6% | 70.2% | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $106.8M | $113.4M | $88.7M | $85.4M | $81.9M | $73.3M | $85.9M |
| SG&A Expense | — | $256.8M | $275.9M | $572.9M | $514.7M | $537.8M | $496.9M | $556.6M |
| Operating Income | — | $-387.2M | $-123.5M | $-257.4M | $-140.6M | $-190.5M | $-289.7M | $7.6M |
| Operating Margin | — | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% | -52.0% | 0.9% |
| Interest Expense | — | — | — | $2.9M | $3.2M | $6.6M | $11.2M | $12.0M |
| Pretax Income | — | $-395.1M | $-123.5M | $-262.2M | $-140.6M | $-57.1M | $-283.6M | $0 |
| Income Tax Expense | — | $-29.2M | $3.8M | $1.1M | $-28.6M | $-29.9M | $-59.9M | $-4.4M |
| Net Income | — | $-365.9M | $-127.3M | $-263.3M | $-112.0M | $-27.2M | $-223.6M | $4.6M |
| Net Margin | — | -44.4% | -15.2% | -35.0% | -16.5% | -3.9% | -40.1% | 0.5% |
| EPS (Basic) | — | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 | $0.06 |
| EPS (Diluted) | — | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 | $0.06 |
| Shares Outstanding (Basic) | 93.5M | 92.6M | 90.6M | 82.8M | 80.6M | 78.0M | 74.8M | 73.5M |
| Shares Outstanding (Diluted) | 93.5M | 92.6M | 90.6M | 82.8M | 80.6M | 78.0M | 74.8M | 76.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |